Consequently, third-generation FLT3 TKIs (e.g., crenolanib, ASP2215) have been designed to overcome resistance and have demonstrated preclinical efficacy in drug-resistant FLT3-ITD AML with acquired mutations (63–65). This evidence concerns the gene FLT3 and acute myeloid leukemia.